SmallCaps Spotlight: Prescient Therapeutics (PTX.ASX) and PTX100’s CTCL pivotal push

## Episode snapshot - **Company:** Prescient Therapeutics (PTX.ASX) - **Lead asset:** **PTX100** (first-in-class small molecule) - **Clinical focus:** **CTCL** (T-cell lymphoma with skin manifestations) - **Programme status:** Global **Phase 2A** dose-optimisation underway

---

## Key discussion points ### 1) What is PTX100 and how does it work? - PTX100 is described as a **small molecule inhibitor of GDTAS1**. - The enzyme is linked to the **RAS pathway**, supporting **prenylation** so mutated RAS proteins can remain active. - By inhibiting GDTAS1, PTX100 aims to **disrupt continuously active RAS-driven signalling** in tumour cells.

### 2) Why CTCL as the first indication? - In earlier **Phase 1B** data for CTCL, management highlighted: - **43% objective response rate** (complete/partial responses) - Remaining patients reported with **stable disease** - Overall **clinical benefit rate of 100%** for the cohort referenced in the discussion - The conversation also framed CTCL as a **high-impact disease** due to skin involvement (itching, disrupted sleep, infections, and social burden).

### 3) Phase 2A progress and recruitment momentum - PTX100 is running as a **global Phase 2A** programme with sites in **Australia, the US and Italy**, and an intention to initiate **France**. - **28 patients dosed** at the time of recording. - A **dose optimisation committee (DOC)** review is planned once there are **10 evaluable patients per arm**. - “Evaluable” is defined in the episode as patients who have received **at least four cycles** of therapy. - The programme is positioned to work towards the **halfway/dose decision milestone towards the end of the year**.

### 4) DOC significance and the next regulatory steps - The DOC is expected to help select the **best dose** among **two dosing arms**. - Following that, the company expects engagement with the **FDA**, including a **Type B meeting**. - The pathway discussed could lead to a **pivotal/registrational approach** depending on outcome and alignment.

### 5) Fast track, orphan designation — what it changes - PTX100 has been discussed as having **FDA fast track designation** in a CTCL subtype (noted in the episode as **Mycosis fungoides**). - The episode also touched on **orphan designation** implications (market exclusivity) and the commercial significance of these regulatory programmes.

### 6) Broader market signals from recent CTCL dealmaking - The episode references a **Sobey**-linked acquisition price (US$580m) for a rival CTCL asset (lacutamab). - Management framed the deal as validating **CTCL’s value** and highlighted differences in fast track scope between assets.

### 7) Platform potential beyond CTCL - Management suggested PTX100’s mechanism targets a pathway relevant across **multiple cancers**, referencing **RAS pathway involvement** across a broad share of tumours. - The plan is to **complete CTCL** first, then explore additional tumour types, potentially beginning with an **orphan approach**.

### 8) How cell therapy assets fit long-term (CellPrime & OmniCar) - The episode described CellPrime and OmniCar as part of the longer-term asset base. - PTX100 is characterised as the near-term priority for **progress and potential partnering**, with an expectation that Cell therapy programmes may require **specialist partners**.

---

## Milestones investors are watching (next 6–12 months) - **End-of-year DOC review** for Phase 2A dose optimisation - **Dose selection** and subsequent discussions on the **shape of the next pivotal/registrational component** - Continued partner engagement as the programme matures (noted as potentially earlier than a full deal, depending on the dose decision timing)

---

## Final takeaway If the DOC review confirms a clearly differentiated dose with favourable **safety and efficacy** signals, the episode suggests PTX100 could move closer to a **registrational/pivotal pathway**, with regulatory momentum supported by earlier **fast track/orphan** status and market validation from CTCL transactions.

## Disclaimer

This podcast is for educational and entertainment purposes only and should not be considered financial advice. All investments carry risk, including the potential loss of principal. Listeners should conduct their own research and consider seeking professional financial advice before making investment decisions.

## Contact & Social

- Website: SmallCapsSpotlight.com.au - Email: hello@smallcapsspotlight.com.au - Twitter: @SmallCapsSpot - LinkedIn: SmallCaps Spotlight

#SmallCaps #ASXInvesting #PTX.ASX #AustralianStocks #Investing #Podcast